Kriya Medical Technologies has obtained a manufacturing license from CDSCO for the KRIVIDA Trivus Respi Panel RT-qPCR Kit, which enables the simultaneous identification of Respiratory Syncytial Virus, Influenza viruses, and SARS-CoV-2 in individuals with respiratory tract infections.

The KRIVIDA Trivus Respi Panel RT-qPCR kit has been rigorously validated by the Indian Council of Medical Research at the National Institute of Virology, Pune, demonstrating exceptional performance with 100% specificity and 99.11% sensitivity.

This kit is renowned for its ability to detect RSV, a virus that causes viral pneumonia in young children and hospitalizations. It is also a common cause of lower respiratory tract diseases in older adults, potentially leading to life-threatening pneumonia and bronchiolitis, making early detection crucial for infants and the elderly.

The Krivida Trivus Respi Panel RT-qPCR Kit facilitates the early identification of influenza, allowing for the swift initiation of targeted antiviral treatments. Additionally, it has the capability to identify co-infections, which are linked to heightened disease severity, greater morbidity, and increased mortality, particularly in individuals with compromised immune systems.

Dr Shanmugapriya, MD, R&D Head, Kriya Medical Technologies, said

“12.9 per cent of infant deaths in India is caused by pneumonia. 29 per cent of infants with pneumonia are infected with Respiratory Syncytial Virus in India. The mortality rate of RSV infection in a healthy infant is 0.5 to 1.7 per cent and is as high as 60 per cent in immunocompromised infants. The rationale behind the design of Krivida Trivus Multiplex RT PCR kit is grounded in the recognition of the fact that timely and accurate diagnosis of RSV is key for avoiding severe forms of pneumonia and death, and this helps in significant reduction in infant mortality rate. We decided to include Influenza detection, as Influenza (A and B) causes 29 per cent of pneumonia in infants and using specific antiviral drug in the earliest phase of illness can reduce the burden of complications."

Anu Moturi, CEO and Founder, Kriya Medical Technologies, said,

“In the wake of the upcoming Flu season, the Krivida Trivus Respi Panel RT-qPCR Kit is timely and essential since it helps with accurate and rapid identification of the responsible pathogens, enabling healthcare providers to initiate appropriate treatments promptly, reducing the risk of complications and improving patient outcomes. It enables accurate identification of causative agents, enabling targeted and specific treatments resulting in an increased number of successful outcomes. Acquiring this license is yet another milestone and a step towards our vision of making good healthcare affordable and accessible to all. The Krivida Trivus Respi Panel RT-qPCR Kit is a testament to our commitment to innovation, addressing critical healthcare needs.”